407 related articles for article (PubMed ID: 15028478)
1. Development of human chorionic gonadotropin subunit-beta promoter-based toxic gene therapy for testicular cancer.
Shirakawa T; Gotoh A; Zhang Z; Kao C; Chung LW; Gardner TA
Urology; 2004 Mar; 63(3):613-8. PubMed ID: 15028478
[TBL] [Abstract][Full Text] [Related]
2. Development of prostate-specific antigen promoter-based gene therapy for androgen-independent human prostate cancer.
Gotoh A; Ko SC; Shirakawa T; Cheon J; Kao C; Miyamoto T; Gardner TA; Ho LJ; Cleutjens CB; Trapman J; Graham FL; Chung LW
J Urol; 1998 Jul; 160(1):220-9. PubMed ID: 9628654
[TBL] [Abstract][Full Text] [Related]
3. Cotargeting tumor and stroma in a novel chimeric tumor model involving the growth of both human prostate cancer and bone stromal cells.
Hsieh CL; Gardner TA; Miao L; Balian G; Chung LW
Cancer Gene Ther; 2004 Feb; 11(2):148-55. PubMed ID: 14695756
[TBL] [Abstract][Full Text] [Related]
4. Chemogene therapy: osteocalcin promoter-based suicide gene therapy in combination with methotrexate in a murine osteosarcoma model.
Cheon J; Ko SC; Gardner TA; Shirakawa T; Gotoh A; Kao C; Chung LW
Cancer Gene Ther; 1997; 4(6):359-65. PubMed ID: 9408606
[TBL] [Abstract][Full Text] [Related]
5. Adenovirus-mediated gene transfer of enhanced Herpes simplex virus thymidine kinase mutants improves prodrug-mediated tumor cell killing.
Wiewrodt R; Amin K; Kiefer M; Jovanovic VP; Kapoor V; Force S; Chang M; Lanuti M; Black ME; Kaiser LR; Albelda SM
Cancer Gene Ther; 2003 May; 10(5):353-64. PubMed ID: 12719705
[TBL] [Abstract][Full Text] [Related]
6. The telomerase reverse transcriptase promoter drives efficacious tumor suicide gene therapy while preventing hepatotoxicity encountered with constitutive promoters.
Majumdar AS; Hughes DE; Lichtsteiner SP; Wang Z; Lebkowski JS; Vasserot AP
Gene Ther; 2001 Apr; 8(7):568-78. PubMed ID: 11319624
[TBL] [Abstract][Full Text] [Related]
7. A survivin-mediated oncolytic adenovirus induces non-apoptotic cell death in lung cancer cells and shows antitumoral potential in vivo.
Li B; Liu X; Fan J; Qi R; Bo L; Gu J; Qian Q; Qian C; Liu X
J Gene Med; 2006 Oct; 8(10):1232-42. PubMed ID: 16900558
[TBL] [Abstract][Full Text] [Related]
8. Osteocalcin promoter-based toxic gene therapy for the treatment of osteosarcoma in experimental models.
Ko SC; Cheon J; Kao C; Gotoh A; Shirakawa T; Sikes RA; Karsenty G; Chung LW
Cancer Res; 1996 Oct; 56(20):4614-9. PubMed ID: 8840973
[TBL] [Abstract][Full Text] [Related]
9. [Adenovirus-mediated double suicide gene selectively kills breast cancer MCF-7 cells in vitro].
Kong H; Huang ZH; Li Q; Yang LC; Yu JL; Li Z
Nan Fang Yi Ke Da Xue Xue Bao; 2008 Jun; 28(6):907-10. PubMed ID: 18583225
[TBL] [Abstract][Full Text] [Related]
10. Gene therapy for prostate cancer: toxicological profile of four HSV-tk transducing adenoviral vectors regulated by different promoters.
Ebara S; Shimura S; Nasu Y; Kaku H; Kumon H; Yang G; Wang J; Timme TL; Aguilar-Cordova E; Thompson TC
Prostate Cancer Prostatic Dis; 2002; 5(4):316-25. PubMed ID: 12627218
[TBL] [Abstract][Full Text] [Related]
11. Human prostate cancer progression models and therapeutic intervention.
Chung LW; Kao C; Sikes RA; Zhau HE
Hinyokika Kiyo; 1997 Nov; 43(11):815-20. PubMed ID: 9436028
[TBL] [Abstract][Full Text] [Related]
12. The role of a HSV thymidine kinase stimulating substance, scopadulciol, in improving the efficacy of cancer gene therapy.
Hayashi K; Lee JB; Maitani Y; Toyooka N; Nemoto H; Hayashi T
J Gene Med; 2006 Aug; 8(8):1056-67. PubMed ID: 16779868
[TBL] [Abstract][Full Text] [Related]
13. Cloning and analysis of human UroplakinII promoter and its application for gene therapy in bladder cancer.
Zhu HJ; Zhang ZQ; Zeng XF; Wei SS; Zhang ZW; Guo YL
Cancer Gene Ther; 2004 Apr; 11(4):263-72. PubMed ID: 14963492
[TBL] [Abstract][Full Text] [Related]
14. In vivo suppression of osteosarcoma pulmonary metastasis with intravenous osteocalcin promoter-based toxic gene therapy.
Shirakawa T; Ko SC; Gardner TA; Cheon J; Miyamoto T; Gotoh A; Chung LW; Kao C
Cancer Gene Ther; 1998; 5(5):274-80. PubMed ID: 9824046
[TBL] [Abstract][Full Text] [Related]
15. Heat-directed suicide gene therapy mediated by heat shock protein promoter for gastric cancer.
Isomoto H; Ohtsuru A; Braiden V; Iwamatsu M; Miki F; Kawashita Y; Mizuta Y; Kaneda Y; Kohno S; Yamashita S
Oncol Rep; 2006 Mar; 15(3):629-35. PubMed ID: 16465423
[TBL] [Abstract][Full Text] [Related]
16. [The efficacy of autocatalytic casapse-3 driven by human telomerase reverse transcriptase promoter on human ovarian carcinoma].
Song Y; Shen K; Yu JR
Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(41):2919-24. PubMed ID: 18261307
[TBL] [Abstract][Full Text] [Related]
17. Transcriptional targeting of virus-mediated gene transfer by the human hexokinase II promoter.
Määttä AM; Korja S; Venhoranta H; Hakkarainen T; Pirinen E; Heikkinen S; Pellinen R; Mäkinen K; Wahlfors J
Int J Mol Med; 2006 Nov; 18(5):901-8. PubMed ID: 17016620
[TBL] [Abstract][Full Text] [Related]
18. A noninvasive approach for assessing tumor hypoxia in xenografts: developing a urinary marker for hypoxia.
Nelson DW; Cao H; Zhu Y; Sunar-Reeder B; Choi CY; Faix JD; Brown JM; Koong AC; Giaccia AJ; Le QT
Cancer Res; 2005 Jul; 65(14):6151-8. PubMed ID: 16024616
[TBL] [Abstract][Full Text] [Related]
19. A tandemly repeated thyroglobulin core promoter has potential to enhance efficacy for tissue-specific gene therapy for thyroid carcinomas.
Takeda T; Yamazaki M; Minemura K; Imai Y; Inaba H; Suzuki S; Miyamoto T; Ichikawa K; Kakizawa T; Mori J; DeGroot LJ; Hashizume K
Cancer Gene Ther; 2002 Oct; 9(10):864-74. PubMed ID: 12224028
[TBL] [Abstract][Full Text] [Related]
20. VP22 does not significantly enhance enzyme prodrug cancer gene therapy as a part of a VP22-HSVTk-GFP triple fusion construct.
Hakkarainen T; Wahlfors T; Meriläinen O; Loimas S; Hemminki A; Wahlfors J
J Gene Med; 2005 Jul; 7(7):898-907. PubMed ID: 15759279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
